Detrez Iris, Van Stappen Thomas, Martín Arranz María D, Papamichael Kostas, Gils Ann
*Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; †IBD Unit and Endoscopy, Department of Gastroenterology and Hepatology, Hospital Universitario La Paz, Madrid, Spain; and ‡Division of Gastroenterology, Center for Inflammatory Bowel Diseases, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Ther Drug Monit. 2017 Aug;39(4):344-349. doi: 10.1097/FTD.0000000000000394.
Since the late 90s, biopharmaceuticals targeting tumor necrosis factor alpha have revolutionized the treatment of moderately to severely active inflammatory bowel disease. The robust efficacy witnessed in many patients stands in stark contrast with the observation of a proportion of patients who fail to respond or who lose response over time. Therapeutic drug monitoring has been proposed as a means to understand and respond to the variability in clinical response and remission. Various treatment algorithms have been proposed, but optimal use of these measurements in daily practice awaits additional prospective validation trials. This review provides an updated overview on the subject of therapeutic drug monitoring of biopharmaceuticals for the management of inflammatory bowel disease and how we could implement its concepts in a changing landscape.
自20世纪90年代末以来，靶向肿瘤坏死因子α的生物制药彻底改变了中度至重度活动性炎症性肠病的治疗方式。许多患者身上见证的强大疗效与一部分患者无反应或随时间失去反应的观察结果形成鲜明对比。治疗药物监测已被提议作为一种了解和应对临床反应及缓解差异的手段。已经提出了各种治疗算法，但在日常实践中对这些测量的最佳应用仍有待更多前瞻性验证试验。本综述提供了关于用于炎症性肠病管理的生物制药治疗药物监测主题的最新概述，以及我们如何在不断变化的形势中应用其概念。
